Sysmex (OTCMKTS:SSMXY - Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.590-0.590 for the period. The company issued revenue guidance of $3.4 billion-$3.4 billion.
Sysmex Price Performance
OTCMKTS:SSMXY traded up $0.18 during trading hours on Wednesday, reaching $18.83. 106,836 shares of the company traded hands, compared to its average volume of 107,132. The stock has a market cap of $11.85 billion, a P/E ratio of 36.37 and a beta of 0.84. The firm's 50-day moving average is $19.20 and its 200-day moving average is $17.59. Sysmex has a 1-year low of $14.38 and a 1-year high of $29.78. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.23 and a quick ratio of 2.40.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.11 earnings per share for the quarter. The business had revenue of $718.13 million for the quarter. Equities research analysts expect that Sysmex will post 0.65 earnings per share for the current fiscal year.
Sysmex Company Profile
(
Get Free Report)
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Featured Articles
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
